Figueroa-Casas P R, Alfonsin A, Arrighi A, Bluvstein G, Del Castillo R, Goldsman T, Inglesi J, Itala J, Novelli J, Monti C
Centro de Reproducción Humana, Hospital Saenz-Peña, Rosario, Argentina.
Maturitas. 1994 Dec;20(2-3):139-44. doi: 10.1016/0378-5122(94)90009-4.
This study reports on the use of a new transdermal delivery system for estrogen replacement therapy. This was a 12 week open multicenter trial using patches that delivered 0.05 mg/24 hour of 17 beta-estradiol applied twice weekly, every 72 hours, with one week interval after each 3 weeks. Results indicate an overall significant improvement on climacteric complaints with a highly significant and time-related reduction in the two most frequent symptoms: hot flushes and night sweating. Neither local nor systemic side effects were prevalent. By the end of treatment mean plasma levels of estradiol and FSH were 50.6 pg/ml and 46.8 mIU/ml, respectively. It is concluded that this new system of transdermal estrogen replacement therapy significantly reduces the main postmenopausal symptoms, produces adequate plasma estradiol levels and allows good compliance to treatment.
本研究报告了一种用于雌激素替代疗法的新型透皮给药系统的使用情况。这是一项为期12周的开放性多中心试验，使用的贴片每周两次、每72小时释放0.05毫克/24小时的17β-雌二醇，每3周后间隔1周。结果表明，更年期症状总体有显著改善，两种最常见症状（潮热和盗汗）有高度显著且与时间相关的减轻。局部和全身副作用均不常见。治疗结束时，雌二醇和促卵泡激素的平均血浆水平分别为50.6皮克/毫升和46.8毫国际单位/毫升。结论是，这种新型透皮雌激素替代疗法系统能显著减轻主要的绝经后症状，产生足够的血浆雌二醇水平，并使患者对治疗有良好的依从性。
